Maren Anderson, President, formed the firm in 2002. The firm's projects involve reimbursement assessments and reimbursement launch plans. We also help with product launches, including working with private and public payers on coverage, coding, and reimbursement. Typically, we focus on U.S. markets, although we work regularly with European and Japanese consultants on global reimbursement. In the U.S., we have considerable experience with Medicare and Medicaid policy, but we also maintain a consulting panel of private health insurance medical and pharmacy management directors, who provide insight into the managed care marketplace.

Previously, Maren co-founded Health Technology Associates, Inc. (HTA) with Wayne Roe and Michael Strauss, M.D. HTA, which was based in Washington, D.C. HTA grew into a 250-member consulting firm and became part of Covance, Inc. in 1996.

Over the course of Maren's 28-year consulting career, she has worked for a comprehensive list of America's major health care companies. A limited list includes: Amgen, C.R. Bard, LifeCell (A KCI Company), Eli Lilly, Genzyme, Johnson and Johnson, Pfizer, Roche, and Solvay. Her recent work has focused on innovative cancer therapeutics, drug/device combinations, and point-of-care diagnostics. In addition, she has worked for small start-up ventures across the country, including manufacturers of infusion pumps, breast biopsy equipment, radioactive seeds for prostate cancer, innovative drug delivery devices, less-invasive surgery equipment, incontinence products, dressings, surgical supplies, prostheses, implants, imaging technology, diagnostic assays, molecular tests, and blood products. Her work has concerned hundreds of products for a myriad of diseases, including asthma, HIV/AIDS, cancer, heart disease, urinary incontinence, gynecological conditions, eye diseases, congenital defects, premature infants, skin ulcers and other skin diseases, orthopedic conditions, psychiatric conditions and neurological illnesses.

A particular specialty is providing reimbursement analysis to venture capitalists and private equity firms considering investments. Frequently, these engagements lead to a relationship with the principals and business development team at the portfolio company. For example, she has done research for Warburg Pincus, Welsh Carson, Hillman Ventures, Versant Ventures, Polaris Ventures, Flagship Ventures, Schroder Ventures, Sanderling Ventures and Spray Ventures. She serves as an expert on reimbursement to other consulting firms, including LEK, and Scientia Advisors. She also gives speeches on health care financing and product marketing to a wide variety of audiences, including nurses and physicians, national public policy groups, and both state and national manufacturer associations.